FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.
Brave MH, Maguire WF, Weinstock C, Zhang H, Gao X, Li F, Yu J, Fu W, Zhao H, Pierce WF, Chang E, Dinin J, Fiero MH, Rahman NA, Tang S, Pazdur R, Kluetz PG, Amiri-Kordestani L, Suzman DL.
Brave MH, et al. Among authors: maguire wf.
Clin Cancer Res. 2024 Nov 1;30(21):4815-4821. doi: 10.1158/1078-0432.CCR-24-1393.
Clin Cancer Res. 2024.
PMID: 39230571
Clinical Trial.